AG-120

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Near Add Your Location

Sorting 4 by

Center of Excellence

Dana-Farber Cancer Institute
Boston, MA
  • Accepting patients

Center of Excellence

The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
  • Accepting patients

Center of Excellence

MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.